01:50 PM EDT, 08/04/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our 12-month target price by $5 to $54, 7.2x our 2025 sales estimate, in line with GH's historical forward average. We lift our 2025 EPS estimate to -$1.87 from -$2.10 and our 2026 estimate to -$1.63 from -$1.76. Q2 EPS of -$0.44, vs -$0.48 in Q2 2024, beat consensus by $0.07. Revenue rose 31% Y/Y, with oncology revenue increasing 22% to $158.7M due to 30% test volume growth, while Biopharma revenue rose 28% to $56.0M from higher GuardantINFINITY volumes and pricing. The emerging Shield screening business contributed $14.8M from approximately 16,000 tests in its third full commercial quarter. GH lifted its 2025 revenue guidance for the second time this year to $915M-$925M (24%-25% growth), up from the prior 19%-20% range. We find it noteworthy that Guardant360 Tissue achieved its $2,000 average selling price target three years ahead of the 2028 schedule. We expect Shield results to continue to grow and see its ADLT status (which increases Medicare pricing to $1,495/test) aiding top-line growth.